ILC1s expressed inhibitory receptors and underwent inhibitory functional conversion in late stage colon cancers while ILC1s in early-stage tumors expressed high levels of activating receptors (KLRD1, NCR1, KLRC2, KLRB1C) while late-stage colon cancers expressed inhibitory markers (KLRE1, KLRA7). This evidence concerns the gene KLRC2 and malignant colon neoplasm.